Although in the majority of patients even a prolonged ALC reduction during DMF treatment may not be “per se” significantly immunosuppressive, further studies will be necessary to evaluate whether ALC recovery after lymphopenia related DMF suspension may correlate with specific previous treatments and individual patient characteristics possibly helping clinicians in better DMD sequencing. This evidence concerns the gene DMD and lymphopenia.